A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, placebo-controlled study using daily doses of up to 1.3 mg/kg/day of
Concerta in the treatment of adults with the DSM-IV diagnosis of attention deficit
hyperactivity disorder (ADHD) (childhood onset). We hypothesize ADHD symptomatology in adults
with DSM-IV ADHD will be responsive to Concerta treatment and Concerta-associated response of
ADHD symptomatology in adults will be sustained over time.
Phase:
Phase 4
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.